New antibody drug aims to shrink advanced tumors in early trial

NCT ID NCT07223125

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dose and check for side effects. Around 360 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial endometrioid adenocarcinoma lung adenocarcinoma nonpapillary renal cell carcinoma ovarian endometrioid adenocarcinoma papillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED-STAGE SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32803, United States
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
NEXT Oncology
RECRUITING

Irving, Texas, 75039, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea